Chief
Sleckman, Barry
Director of Clinical Education
Eby, Charles
Director of Clinical Services
Lublin, Douglas
Blinder, Morey
Burnham, Carey-Ann
Dantas, Gautam
Despotis, George
Dunne, Michael
Frater, John
Gordon, Jeffrey
Gronowski, Ann
Grossman, Brenda
Hassan, Anjum
Kreisel, Friederike
Kulkarni, Shashikant
Ladenson, Jack
Liu, Jinglan
Mohanakumar, Thalachallour
Nagarajan, Rakesh
Nguyen, Tu-Dung
Oltz, Eugene
Payton, Jacqueline
Scott, Mitchell
Turk, John
Wang, David
Watson, Mark
Yaseen, Nabeel
Zhang, Lijuan
|
Barry Sleckman, MD, PhD
Conan Professor of Pathology and Immunology
Chief of LGM Division | |  |
Dr. Sleckman joined the LGM Division in 2005 and became the director in 2008. He is also the Co-Medical Director of the Clinical Immunology Laboratory. Dr. Sleckman’s laboratory is focused on understanding the genetic programs that promote normal lymphocyte development and on the cellular responses to and repair of DNA damage. |
|
Charles Eby, MD
Associate Professor of Pathology and Immunology
Director of Clinical Education | |  |
Dr. Eby joined the LGM Division in 1991. He is the Director of the Clinical Pathology Residency program and Director of the Hematology and Hemostasis Laboratories at Barnes-Jewish Hospital. Dr. Eby’s research is in the genetic contribution to variability of warfarin dosing through analysis of SNPs in cytochrome 2C9, VKOR and coagulation factors VII and II genes. Dr. Eby’s laboratory also studies molecular risk factors for venous thromboembolic events and acquired functional iron deficiency in cancer patients receiving recombinant erythropoietin. |
|
Douglas Lublin, MD, PhD
Professor of Pathology and Immunology
Director of Clinical Services | |  |
Dr. Lublin joined the LGM Division in 1987. He is Associate Director for Clinical Affairs, attends on the Transfusion Medicine Service and is the Chairman of the Laboratory Steering Committee. Dr. Lublin’s research is focused on the discovery of novel blood group antigens and on the development of tests for their detection. |
|
Morey Blinder, MD
Associate Professor of Medicine | |  |
Dr. Blinder joined the LGM Division in 1990. He is the Medical Director of Wohl Hematology Laboratory and an Associate Member of the Siteman Cancer Center. Dr. Blinder’s research interests include the diagnosis and treatment of red blood cell disorders as well as platelet and coagulation abnormalities. His laboratory is developing alternative assays to aid in the management of anticoagulant dosing for patients with thromboembolic disease. |
|
Carey-Ann Burnham, PhD
Instructor of Pediatrics | |  |
Dr. Carey-Ann Burnham joined the LGM Division in July 2009. She is the Medical Director of the microbiology laboratory at St. Louis Children’s Hospital. Dr. Burnham graduated from the Medical and Public Health Microbiology Fellowship at Washington University School of Medicine in 2009. Her research interests are in the area of molecular test development for fungal infections and in the development of tests for polymicrobial infections, specifically those involved in lung infections in patients with cystic fibrosis. |
|
Gautam Dantas, PhD
Assistant Professor of Pathology and Immunology | |  |
Dr. Gautam Dantas joined the LGM Division as an Assistant Professor of Pathology and Immunology and a member of the Center for Genome Sciences in August 2009. His research interests lie at the interface of microbial genomics and biochemistry, synthetic biology and structural biology, with a specific focus on understanding microbial reservoirs of antibiotic resistance and in engineering microbial catalysis of plant biomass into value chemicals. |
|
George Despotis, MD
Associate Professor of Pathology and Immunology
Medical Director of Transfusion Medicine | |  |
Dr. Despotis joined the LGM Division in 1997. He is Chair of the Barnes-Jewish Hospital Transfusion Committee. Dr. Despotis’ research interests are in the validation of point-of-care coagulation and platelet function instruments with respect to accuracy, reproducibility and ability to identify patients at risk for bleeding. His clinical interests reside within blood banking and transfusion medicine. |
|
Michael Dunne
Professor of Pathology and Immunology
Medical Director of Clinical Microbiology | |  |
Dr. Dunne joined the LGM Division in 2000. He is the Medical Director of Barnes-Jewish Hospital Clinical Microbiology Laboratory and the Director of the Medical and Public Health Microbiology Fellowship. Dr. Dunne’s research interests include bacterial biofilms in human infection, molecular epidemiology and the development of assays for use in the diagnostic microbiology laboratory. |
|
John Frater, MD
Assistant Professor of Pathology and Immunology | |  |
Dr. Frater joined the LGM Division in 2006. Dr. Frater’s clinical interests are in hematopathology. |
|
Jeffrey Gordon, MD
Dr. Robert J. Glaser Distinguished University Professor
Director of the Center for Genome Sciences | |  |
Dr. Gordon joined the LGM Division in 2008. His laboratory characterizes the genomic and metabolic foundations of mutually beneficial relationships between gut microbial communities and their human hosts. Dr. Gordon has a long-standing commitment to creating an interdisciplinary training environment for students and postdocs interested in human microbial ecology and metagenomics. Together with colleagues, he is conducting clinical trials with twins living in developing as well as industrialized countries. |
|
Ann Gronowski, PhD
Associate Professor of Pathology and Immunology
Associate Medical Director of Clinical Chemistry | |  |
Dr. Gronowski joined the LGM Division in 1998. She is the Co-Medical Director of Clinical Chemistry, Serology and Immunology at Barnes-Jewish Hospital, and Co-Director of the Clinical Chemistry Fellowship program. Dr. Gronowski’s research interests are in the development of diagnostic tests to evaluate medical conditions during pregnancy. |
|
Brenda Grossman, MD
Associate Professor of Pathology and Immunology
Medical Director of the Blood Bank | |  |
Dr. Grossman joined the LGM Division in 2009. She is the Medical Director of the Blood Bank and attends on the Transfusion Medicine service. Dr. Grossman’s research is focused on clinical aspects of transfusion medicine, especially as it applies to transplant patients. |
|
Anjum Hassan, MD
Assistant Professor of Pathology and Immunology | |  |
Dr. Hassan joined the LGM Division in 2006. She is the Assistant Director of the Fluorescent in-situ Hybridization (FISH) Laboratory. Dr. Hassan’s research focuses on signal transduction pathways that play a role in the pathogenesis of lymphocytic leukemia. |
|
Friederike Kreisel, MD
Assistant Professor of Pathology and Immunology | |  |
Dr. Kreisel joined the LGM Division in 2006. Dr. Kreisel’s clinical interests are in hematopathology. Her research focuses on the developmental origin of plasmacytoid dendritic cells. |
|
Shashikant Kulkarni, PhD
Assistant Professor of Pathology and Immunology
Medical Director of CytoGenomics | |  |
Dr. Kulkarni joined the LGM Division in 2007. He is the Medical Director of Clinical CytoGenomics. Dr. Kulkarni¹s principle research interest is to study Chromosomal Structural Variants. His lab uses genome-wide tools for the molecular characterization of these variants associated with human development and cancer. He has clinically validated a ³chromosomal- microarray/molecular karyotype² which allows detection of deletions at kilobase-level, a Major Leap forward as compared to the megabase-level resolution for conventional chromosome analysis. He is also the Director of the Cytogenetics Fellowship training program. |
|
Jack Ladenson, PhD
Oree M. Carroll and Lillian B. Ladenson Professor of Clinical Chemistry
Co-Medical Director of Clinical Chemistry | |  |
Dr. Ladenson joined the LGM Division in 1972. He has served in many key positions including Interim Director From 2003-2008. Dr. Ladenson’s laboratory has focused on the development of biomarkers for clinical diagnosis. He developed the quantitative test for CK-MB and the first practical Troponin I assay. His current work involves tests for identifying brain injury such as stroke, Alzheimer's disease, etc. He is also Director of clinical pathology programs for Pathologists Overseas, Inc., an organization dedicated to upgrading clinical diagnostic capability in developing countries. |
|
Jinglan Liu, PhD
Assistant Professor of Pathology and Immunology | |  |
Dr. Jinglan Liu joined the LGM Division as an Assistant Professor of Pathology and Immunology in September 2009. She is also the Associate Medical Director of the Cytogenomics and Molecular Pathology Laboratory. Dr. Liu received her PhD degree from Temple University School of Medicine in Philadelphia and completed her postdoctoral training at Stanford University School of Medicine and at the Children's Hospital of Philadelphia. She is ABMG board certified in clinical molecular genetics and is board eligible in clinical cytogenetics. Her research interest is in cohesin biology and the development of molecular and cytogenetic tests. |
|
Thalachallour Mohanakumar, PhD
Jacqueline G. and William E. Maritz Professor of Surgery
Medical Director of the Histocompatibility Laboratory | |  |
Dr. Mohanakumar joined the LGM Division in 1987. He is the Medical Director of Histocompatibility and Immunogenetics Laboratory and Director of the Islet Cell Core Facility. Dr. Thalachallour’s research is focused on the role of MHC in transplantation and various disease states, including auto-immunity and cancer. |
|
Rakesh Nagarajan, MD, PhD
Associate Professor of Pathology and Immunology | |  |
Dr. Nagarajan joined the LGM Division in 2003. He is Director of the Neuroscience Blueprint Biomedical Informatics Core and Director of the Clinical and Translational Science Award Biomedical Informatics Program. Dr. Nagarajan’s laboratory focuses on clinical and biomedical informatics research; development of software applications, which will simultaneously co-analyze and co-visualize functional genomics datasets, gene annotation, and clinicopathological data; and utilization of these heuristic algorithms in order to identify potential diagnostic markers and putative therapeutic targets. |
|
Tu-Dung Nguyen, MD, PhD
Assistant Professor of Pathology and Immunology | |  |
Dr. Nguyen joined the LGM Division in 2008. Her clinical interests include Hematopathology and Molecular Genetic Pathology. Her research interests are focused on the molecular genetic and immunohistochemical attributes of human hematopoietic tumors. These include acute and chronic leukemias, lymphomas and myeloproliferative neoplasms. |
|
Eugene Oltz, PhD
Professor of Pathology and Immunology | |  |
Dr. Eugene Oltz joined the LGM Division in 2009. His laboratory is focused on the biology of chromatin and how modifications in chromatin can contribute to cellular transformation. Dr. Oltz’s lab has been a leader in our understanding of how specific histone modifications are generated and how they can regulate gene transcriptions and programmed gene rearrangements. |
|
Jacqueline Payton, MD, PhD
Instructor of Pathology and Immunology
Medical Director of Molecular Diagnostics | |  |
Dr. Payton joined the LGM Division in 2008. She is the Medical Director of Molecular Diagnostics and Associate Director for Bioinformatics. Dr. Payton’s research interests are in the development of genomic and epigenomic tests applicable to a wide variety of diseases. She completed Washington University School of Medicine’s Clinical Pathology Residency program where she served as Chief Resident. |
|
Mitchell Scott, PhD
Professor of Pathology and Immunology
Co-Medical Director of Clinical Chemistry | |  |
Dr. Scott joined the LGM Division in 1987. He is Co-Director of the Clinical Chemistry Fellowship program and Co-Medical Director of the Clinical Chemistry Laboratory. Dr. Scott’s research interests focus on clinical chemistry test development in the areas of electrolytes and blood gas evaluation and in the in area of diagnostic immunoassays. |
|
John Turk, MD, PhD
Professor of Pathology and Immunology | |  |
Dr. Turk joined the LGM Division in 1988. He is Director of the Mass Spectrometry Facility and Drug Analysis Laboratory. Dr. Turk’s laboratory is focused on understanding the signaling events that lead to insulin secretion and on the role of PLA2 enzymes in activation of monocytes and their differentiation into vascular wall foam cells in diabetes-associated atherogenesis. |
|
David Wang, PhD
Assistant Professor of Molecular Microbiology | |  |
Dr. Wang joined the LGM Division in 2004. Dr. Wang is one of the Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease. His laboratory focuses on identifying and characterizing novel viruses responsible for human diseases. To this end, they integrate a variety of experimental methodologies that cross many disciplines including molecular biology, virology, genomics, epidemiology and bioinformatics. |
|
Mark Watson, MD, PhD
Associate Professor of Pathology and Immunology
Director of Tissue Procurement and Multiplexed Gene Analysis Laboratories | |  |
Dr. Watson joined the LGM Division in 1996. He is Director of the Tissue Procurement Core Facility and Multiplexed Gene Analysis Core Facility at the Siteman Cancer Center, Director of the Central Specimen Bank at the American College of Surgeons Oncology Group and Director of the Laboratory for Clinical Genomics. Dr. Watson’s laboratory is focused on the development and translation of molecular diagnostic tests for a variety of genetic diseases and cancer. |
|
Nabeel Yaseen, MD, PhD
Associate Professor of Pathology and Immunology
Director of Hematopathology Section | |  |
Dr. Yaseen joined the LGM Division in 2007. He is the Director of the Hematopathology Section. Dr. Yaseen’s laboratory studies the molecular pathways responsible for acute myeloid leukemia (AML). |
|
Lijuan Zhang, PhD
Assistant Professor of Pathology and Immunology | |  |
Dr. Zhang joined the LGM Division in 2002. Her laboratory focuses on Glycosaminoglycans (GAG) research including GAG isolation, quantification, bioassays, structural analysis by capillary HPLC coupled MS and GAG structure-based bioinformatics. Her long-term goal is to develop GAG-based pharmaceuticals, a largely untapped source of future medicine. |
|
|
|
